OncoMatch/Clinical Trials/NCT06857175
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma
Is NCT06857175 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including BL-B01D1 and Docetaxel or Paclitaxel for urothelial carcinoma.
Treatment: BL-B01D1 · Docetaxel or Paclitaxel — This trial is a registered phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic urothelial carcinoma after failure of PD-1/PD-L1 monoclonal antibody and platinum-based chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Urothelial Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Patients with unresectable locally advanced or metastatic urothelial carcinoma who had failed platinum-based chemotherapy
Must have received: anti-PD-1 therapy or anti-PD-L1 therapy
Patients with unresectable locally advanced or metastatic urothelial carcinoma who had failed ... PD-1/PD-L1 inhibitors
Cannot have received: antibody-drug conjugate targeting topoisomerase I inhibitors
Frontline received ADCs targeting topoisomerase I inhibitors
Cannot have received: EGFR inhibitor
Frontline received ... EGFR
Cannot have received: HER3 inhibitor
Frontline received ... HER3
Cannot have received: taxane (paclitaxel, docetaxel)
The front line had received both paclitaxel and docetaxel
Cannot have received: autologous or allogeneic stem cell transplant
Had a history of autologous or allogeneic stem cell transplantation
Lab requirements
Blood counts
If blood transfusion and colony-stimulating factor were not allowed within 14 days before randomization, the organ function level had to meet the requirements
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; If blood transfusion and colony-stimulating factor were not allowed within 14 days before randomization, the organ function level had to meet the requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06857175 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody-drug conjugate targeting topoisomerase I inhibitors, EGFR inhibitor, HER3 inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages